Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.

The New England journal of medicine - 1 Jan 2026

Jänne Pasi A, Planchard David, Kobayashi Kunihiko, Yang James Chih-Hsin, Liu Ying, Valdiviezo Natalia, Kim Tae Min, Jiang Liyan, Kagamu Hiroshi, Yanagitani Noriko, Wang Jialei, Biswas Bivas, Poltoratskiy Artem, Neron Yeni, Rojas Carlos, Koubkova Leona, Escriu Carles, Ezeife Doreen A, Mann Helen, Armenteros-Monterroso Elena, Rukazenkov Yuri, Lee Chee Khoon

Abstract excerpt

BACKGROUND: The primary analysis of this trial showed that first-line treatment with osimertinib plus chemotherapy with a platinum-based agent and pemetrexed led to significantly longer progression-free survival than osimertinib monotherapy among patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC). Results from the planned final analysis of overall survival...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboplatin

Share to Cisplatin

Share to Indoles

Share to Pemetrexed

Share to Progression-Free Survival

Share to Pyrimidines

Source

Identifiers

PMID: 41104938
DOI: 10.1056/NEJMoa2510308

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.PMID 41104938Read ↗

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.Semantic proximity Read ↗

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.Semantic proximity Read ↗

Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.Semantic proximity Read ↗

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.Semantic proximity Read ↗

Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.Semantic proximity Read ↗

Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.Semantic proximity Read ↗

Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion.Semantic proximity Read ↗

Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.Semantic proximity Read ↗

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.